BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 2543305)

  • 1. [The prospect for cisplatin analogs from the experimental standpoint].
    Tashiro T
    Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-2):1358-65. PubMed ID: 2543305
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antitumor activity of a new platinum(II) complex with low nephrotoxicity and genotoxicity.
    Marzano C; Bettio F; Baccichetti F; Trevisan A; Giovagnini L; Fregona D
    Chem Biol Interact; 2004 Jun; 148(1-2):37-48. PubMed ID: 15223355
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Mechanisms for resistance and cross-resistance patterns of cisplatin-resistant tumor lines].
    Tashiro T
    Gan To Kagaku Ryoho; 1990 Mar; 17(3 Pt 2):509-14. PubMed ID: 2321979
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Preclinical and clinical evaluation of toxicity and antitumor activity of cisplatin analogues].
    Ariyoshi Y; Ota K
    Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-2):1379-85. PubMed ID: 2658826
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modulatory effect of axial and equatorial ligands on antitumor activities of trans-1R,2R-diaminocyclohexane platinum(IV) complexes.
    Siddik ZH; al-Baker S; Thai G; Khokhar AR
    Anticancer Drug Des; 1994 Apr; 9(2):139-51. PubMed ID: 8166929
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical antitumor evaluation of bis-acetato-ammine-dichloro-cyclohexylamine platinum(IV): an orally active platinum drug.
    Kelland LR; Abel G; McKeage MJ; Jones M; Goddard PM; Valenti M; Murrer BA; Harrap KR
    Cancer Res; 1993 Jun; 53(11):2581-6. PubMed ID: 8388318
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of carrier ligand in platinum resistance of human carcinoma cell lines.
    Schmidt W; Chaney SG
    Cancer Res; 1993 Feb; 53(4):799-805. PubMed ID: 8428361
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sensitivity to novel platinum compounds of panels of human lung cancer cell lines with acquired and inherent resistance to cisplatin.
    Twentyman PR; Wright KA; Mistry P; Kelland LR; Murrer BA
    Cancer Res; 1992 Oct; 52(20):5674-80. PubMed ID: 1327513
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antitumor activity and cross-resistance studies with Pt-ascorbato complexes.
    Hrubisko M; Balázová E; Kiss F; Kovácová J; Ujházy V
    Neoplasma; 1989; 36(6):651-7. PubMed ID: 2615869
    [TBL] [Abstract][Full Text] [Related]  

  • 10. cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice.
    Raynaud FI; Boxall FE; Goddard PM; Valenti M; Jones M; Murrer BA; Abrams M; Kelland LR
    Clin Cancer Res; 1997 Nov; 3(11):2063-74. PubMed ID: 9815598
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tetravalent platinum complexes with ammine/amine carrier ligand configuration: circumvention of platinum resistance in vivo.
    Siddik ZH; Thai G; Yoshida M; Zhang YP; Khokhar AR
    Anticancer Drug Des; 1994 Dec; 9(6):495-509. PubMed ID: 7880375
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro histoculture drug response assay and in vivo blood chemistry of a novel Pt(IV) compound, K104.
    Kwon YE; Park JY; Kim WK
    Anticancer Res; 2007; 27(1A):321-6. PubMed ID: 17352249
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis, cytotoxicity and antitumor activity of platinum(II) complexes of cyclopentanecarboxylic acid hydrazide.
    Kushev D; Gorneva G; Taxirov S; Spassovska N; Grancharov K
    Biol Chem; 1999 Nov; 380(11):1287-94. PubMed ID: 10614821
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Experimental evaluation of cisplatin analogous in urogenital cancer].
    Machida T; Akasaka Y
    Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-2):1386-92. PubMed ID: 2658827
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ascorbato(1,2-diaminocyclohexane):platinum(II) complexes, a new series of water-soluble antitumor drugs.
    Hacker MP; Khokhar AR; Brown DB; McCormack JJ; Krakoff IH
    Cancer Res; 1985 Oct; 45(10):4748-53. PubMed ID: 4040806
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis, in vitro cytotoxic and antiviral activity of cis-[Pt(R(-) and S(+)-2-alpha-hydroxybenzylbenzimidazole)2Cl2] complexes.
    Gökçe M; Utku S; Gür S; Ozkul A; Gümüş F
    Eur J Med Chem; 2005 Feb; 40(2):135-41. PubMed ID: 15694648
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Pharmacological approach to the platinum compounds].
    Sasaki Y
    Gan To Kagaku Ryoho; 1992 Apr; 19(4):456-62. PubMed ID: 1313667
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New synthetic route to [bis-1,2-(aminomethyl)benzene]dichloroplatinum(II) complexes, screening for cytotoxic activity in cisplatin-sensitive and resistant human cancer cell lines, and reaction with glutathione.
    Rinke K; Grünert R; Bednarski PJ
    Pharmazie; 2001 Oct; 56(10):763-9. PubMed ID: 11683118
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel mechanisms of platinum drug resistance identified in cells selected for resistance to JM118 the active metabolite of satraplatin.
    Samimi G; Kishimoto S; Manorek G; Breaux JK; Howell SB
    Cancer Chemother Pharmacol; 2007 Feb; 59(3):301-12. PubMed ID: 16770583
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel trans platinum complexes: comparative in vitro and in vivo activity against platinum-sensitive and resistant murine tumours.
    Goddard PM; Orr RM; Valenti MR; Barnard CF; Murrer BA; Kelland LR; Harrap KR
    Anticancer Res; 1996; 16(1):33-8. PubMed ID: 8615631
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.